Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) has announced the presentation of Phase 1 data and plans for an adaptive Phase 2 field study of TNX-4800, a long-acting monoclonal antibody candidate for the prevention of Lyme disease. The company expects to initiate the Phase 2 study in the first half of 2027, pending agreement with the U.S. Food and Drug Administration.
TNX-4800 is designed to target Borrelia burgdorferi, the bacterium that causes Lyme disease, and is intended to provide extended protection during tick season. The candidate was licensed from UMass Chan Medical School. In announcing the data, Tonix highlighted the potential advantages of a monoclonal antibody approach over traditional vaccines, noting that there are currently no approved prophylactic options for Lyme disease in the United States.
The news is significant because Lyme disease is the most common vector-borne disease in the U.S., with hundreds of thousands of cases reported annually. Current prevention relies on tick avoidance and early treatment, but no vaccine or preventive antibody is available for humans. A successful prophylactic could fill a major public health gap.
Tonix Pharmaceuticals is a fully integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments. The company recently received approval for TONMYA (cyclobenzaprine HCl sublingual tablets 2.8 mg), the first new treatment for fibromyalgia in over 15 years. Tonix’s CNS commercial infrastructure also supports its acute migraine products, Zembrace SymTouch and Tosymra.
Beyond TNX-4800, Tonix is advancing a pipeline that includes TNX-2900 for Prader-Willi syndrome, which is Phase 2 ready, and TNX-1500, a third-generation CD40 ligand inhibitor for preventing kidney transplant rejection. The company is also evaluating TONMYA in Phase 2 trials for major depressive disorder and acute stress disorder.
For more details on the Phase 1 data and Phase 2 plans, the full press release is available at https://ibn.fm/yB2M8. Latest news and updates on TNXP can be found in the company’s newsroom at https://ibn.fm/TNXP.
